New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePGPIPN vs Adipotide

PGPIPN vs Adipotide

Side-by-side comparison of key properties, dosing, and research.

Immune Support
PGPIPN
Fat Loss & Metabolic
Adipotide
Summary
PGPIPN is a bioactive hexapeptide (Pro-Gly-Pro-Ile-Pro-Asn) derived from beta-casein during enzymatic digestion. It exhibits anti-inflammatory properties via opioid receptor modulation and cytokine suppression, making it relevant for gut health, systemic inflammation, and as a component of casein-derived functional foods.
Adipotide (FTPP) is a chimeric proapoptotic peptide that selectively targets and destroys blood vessels feeding white adipose tissue. It binds prohibitin on the vasculature of fat tissue, delivering a proapoptotic sequence that induces cell death in fat-specific blood vessels, causing targeted fat tissue regression.
Half-Life
Estimated 30-120 minutes (peptide degradation)
Estimated 2-4 hours
Admin Route
Oral, Subcutaneous (research)
Subcutaneous, Intravenous (research)
Research
Typical Dose
200-500 mg per day
Not established for humans; primate studies used 0.1-1 mg/kg
Frequency
Once or twice daily
Daily for 4 weeks (research protocol)
Key Benefits
  • Anti-inflammatory effects via cytokine suppression
  • Gut mucosal protection and intestinal barrier support
  • Opioid receptor modulation for gut motility regulation
  • Potential analgesic activity via central and peripheral opioid pathways
  • Explored for inflammatory bowel conditions and gut dysbiosis
  • Natural origin (food-derived) with favorable safety profile
  • Targeted reduction of white adipose tissue
  • Promotes fat vasculature apoptosis without systemic toxicity
  • Demonstrated significant fat loss in primate studies
  • Potential for visceral and subcutaneous fat reduction
  • Novel non-hormonal mechanism distinct from GLP-1 agonists
  • Explored for obesity and metabolic syndrome
Side Effects
  • Generally very well-tolerated given food-derived origin
  • Theoretical opioid-mediated constipation at high doses
  • Rare milk protein allergy in casein-sensitive individuals
  • Renal toxicity observed in primate studies (transient, dose-dependent)
  • Dehydration and electrolyte imbalances in research
  • Weight regain upon cessation
  • Limited human data; side effect profile largely from animal studies
Stacks With